Impact of type 2-targeted therapies on respiratory infection risk
puremagic
1个月前
86
10
已完结
1. 系统已在2026-02-12 12:50:39对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
K Smiley, N Zuhdi, B Geng
Current Opinion in Allergy and …, 2026
journals.lww.com
T2-modulating biologics not only control allergic inflammation but also restore epithelial and immune homeostasis, contributing to maintained or reduced respiratory infection risk. These therapies represent a dual benefit of barrier repair and immune rebalancing. Further studies are warranted to evaluate long-term infection outcomes in high-risk populations.
